

INVESTOR WEBINAR

- **PYC will hold an investor webinar on Friday 22 May 2026 at 8:00am AWST / 10:00am AEDT**

PERTH, Australia and SAN FRANCISCO, California – 12 May 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) will hold an investor webinar to update shareholders on progress made in CY26 across its pipeline of investigational drug candidates.

The webinar will be held on Friday 22 May 2026 at 8:00am AWST (10:00am AEDT).

Shareholders are invited to attend in person at the McCusker Auditorium at the Harry Perkins Institute North Campus in Nedlands, Western Australia or register for the online webinar via the link below:

https://us02web.zoom.us/webinar/register/WN_R_CJC33CSp2li_npJCoeAA

After registering, you will receive a confirmation email containing information about joining the webinar.

This announcement was approved for release by the CEO of PYC Therapeutics Limited.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development ¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

CONTACT US

Investor relations and media contact
investor@pyctx.com

